drugset
drugset / Trial / NCT02542696

Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

NCT02542696 ↗

Phase 3 Completed 496 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Timeline

Start
2015-08-31
Primary completion
2022-11-08
Completion
2022-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject APL-130277 Unknown 10 mg Other
Subject APL-130277 Unknown 15 mg Other
Subject APL-130277 Unknown 20 mg Other
Subject APL-130277 Unknown 25 mg Other
Subject APL-130277 Unknown 30 mg Other
Subject APL-130277 Unknown 35 mg Other

Indications

Parkinson disease